{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:41:15Z","timestamp":1785235275340,"version":"3.55.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["U01AI116086"],"award-info":[{"award-number":["U01AI116086"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["17\/15, W16\/72"],"award-info":[{"award-number":["17\/15, W16\/72"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Broadly neutralizing antibodies (bNAbs) are currently being assessed in clinical trials for their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have advantages over full antibodies as their smaller size permits improved diffusion into mucosal tissues and facilitates vector-driven gene expression. We have previously shown that scFv of bNAbs individually retain significant breadth and potency. Here we tested combinations of five scFv derived from bNAbs CAP256-VRC26.25 (V2-apex), PGT121 (N332-supersite), 3BNC117 (CD4bs), 8ANC195 (gp120-gp41 interface) and 10E8v4 (MPER). Either two or three scFv were combined in equimolar amounts and tested in the TZM-bl neutralization assay against a multiclade panel of 17 viruses. Experimental IC<jats:sub>50<\/jats:sub> and IC<jats:sub>80<\/jats:sub> data were compared to predicted neutralization titers based on single scFv titers using the Loewe additive and the Bliss-Hill model. Like full-sized antibodies, combinations of scFv showed significantly improved potency and breadth compared to single scFv. Combinations of two or three scFv generally followed an independent action model for breadth and potency with no significant synergy or antagonism observed overall although some exceptions were noted. The Loewe model underestimated potency for some dual and triple combinations while the Bliss-Hill model was better at predicting IC<jats:sub>80<\/jats:sub> titers of triple combinations. Given this, we used the Bliss-Hill model to predict the coverage of scFv against a 45-virus panel at concentrations that correlated with protection in the AMP trials. Using IC<jats:sub>80<\/jats:sub> titers and concentrations of 1\u03bcg\/mL, there was 93% coverage for one dual scFv combination (3BNC117+10E8v4), and 96% coverage for two of the triple combinations (CAP256.25+3BNC117+10E8v4 and PGT121+3BNC117+10E8v4). Combinations of scFv, therefore, show significantly improved breadth and potency over individual scFv and given their size advantage, have potential for use in passive immunization.<\/jats:p>","DOI":"10.3389\/fimmu.2021.734110","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:08:30Z","timestamp":1631768910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth"],"prefix":"10.3389","volume":"12","author":[{"given":"Rebecca T.","family":"van Dorsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eaao4235","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection Against a Mixed SHIV Challenge by a Broadly Neutralizing Antibody Cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00908-15","article-title":"Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates From Mucosal Simian-Human Immunodeficiency Virus Infection","volume":"89","author":"Saunders","year":"2015","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody Protects Macaques Against Vaginal Challenge With a Pathogenic R5 Simian\/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro","volume":"75","author":"Parren","year":"2001","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 Vaccine Development and Therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science (80-)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and Bivalent Subtype C Gp120\/MF59 HIV-1 Vaccine in Low-Risk, HIV-Uninfected, South African Adults: A Phase 1\/2 Trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of Gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination With ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12977-018-0449-7","article-title":"Adeno-Associated Virus Gene Delivery of Broadly Neutralizing Antibodies as Prevention and Therapy Against HIV-1 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1108 Medical Microbiology Marit Van Gils, M.J.Vangils@Amc","volume":"15","author":"Lin","year":"2018","journal-title":"Retrovirology"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-415847-4.00071-9","article-title":"Passive Immunization","volume-title":"Mucosal Immunology","author":"Marcotte","year":"2015"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11904-017-0352-1","article-title":"Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System","volume":"14","author":"Bhiman","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and Efficacy of VRC01 Broadly Neutralising Antibodies in Adults With Acutely","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103203","article-title":"Pharmacokinetics and Predicted Neutralisation Coverage of VRC01 in HIV-Uninfected Participants of the Antibody Mediated Prevention (AMP) Trials","volume":"64","author":"Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002639","article-title":"Feasibility and Successful Enrollment in a Proof-Of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody","volume":"87","author":"Edupuganti","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002649","article-title":"A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa","volume":"87","author":"Mgodi","year":"2021","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PloS Pathog"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03136-14","article-title":"Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes","volume":"89","author":"Kong","year":"2015","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of Conventional & Bispecific Broadly Neutralizing Antibodies for Prevention of HIV-1 Subtype A, C & D Infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PloS Pathog"},{"key":"B21","unstructured":"CAPRISA Studies | CAPRISA2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e042247","DOI":"10.1136\/bmjopen-2020-042247","article-title":"Assessing the Safety and Pharmacokinetics of the Anti-HIV Monoclonal Antibody CAP256V2LS Alone and in Combination With VRC07-523LS and PGT121 in South African Women: Study Protocol for the First-in-Human CAPRISA 012B Phase I Clinical Trial","volume":"10","author":"Mahomed","year":"2020","journal-title":"BMJ Open"},{"key":"B23","unstructured":"Phase 1 Broadly Neutralizing Antibody Efforts\n            KarunaST\n          2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-110118-045506","article-title":"Broadly Neutralizing Antibodies for HIV Prevention","volume":"71","author":"Karuna","year":"2020","journal-title":"Annu Rev Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of Drug Combinations: Current Methodological Landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03080-19","article-title":"A Bispecific Antibody That Simultaneously Recognizes the V2-And V3-Glycan Epitopes of the Hiv-1 Envelope Glycoprotein is Broader and More Potent Than Its\u00a0Parental Antibodies","volume":"11","author":"Davis-Gardner","year":"2020","journal-title":"MBio"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies With Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00384-18","article-title":"Targeting the HIV-1 Spike and Coreceptor With Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry","volume":"92","author":"Khan","year":"2018","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1128\/JVI.05848-11","article-title":"Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations","volume":"86","author":"West","year":"2012","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001119","article-title":"Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies","volume":"73","author":"Song","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-019-0493-y","article-title":"Engineering and Characterising a Novel, Highly Potent Bispecific Antibody Imab-CAP256 That Targets HIV-1","volume":"16","author":"Moshoette","year":"2019","journal-title":"Retrovirology"},{"key":"B32","unstructured":"Pharmacokinetics and Biodistribution of Genetically-Engineered Antibodies\n            ColcherD\n            PavlinkovaG\n            BeresfordG\n            BoothBJ\n            ChoudhuryA\n            BatraSK\n          1998"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic Properties of IgG and Various Fc Fusion Proteins in Mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-013-0597-4","article-title":"Rapid Tumor Penetration of a Single-Chain Fv and Comparison With Other Immunoglobulin Forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzr061","article-title":"Half-Life Extension of a Single-Chain Diabody by Fusion to Domain B of Staphylococcal Protein A","volume":"25","author":"Unverdorben","year":"2012","journal-title":"Protein Eng Des Sel"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01568","article-title":"CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals From HIV-1 Subtype C Infected Indian Children","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100687","article-title":"Synergistic Inhibition of Cell-to-Cell HIV-1 Infection by Combinations of Single Chain Variable Fragments and Fusion Inhibitors","volume":"20","author":"Alam","year":"2019","journal-title":"Biochem Biophys Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01533-19","article-title":"Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived From Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope","volume":"94","author":"van Dorsten","year":"2020","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e51897","DOI":"10.3791\/51897","article-title":"Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach","volume":"92","author":"Portolano","year":"2014","journal-title":"J Vis Exp"},{"key":"B40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1385\/1-59259-890-0:571","article-title":"Protein Identification and Analysis Tools on the ExPASy Server","volume-title":"The Proteomics Protocols Handbook","author":"Gasteiger","year":"2005"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00198-11","article-title":"The Neutralization Breadth of HIV-1 Develops Incrementally Over Four Years and Is Associated With CD4+ T Cell Decline and High Viral Load During Acute Infection","volume":"85","author":"Gray","year":"2011","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental Pathway for Potent V1V2-Directed HIV-Neutralizing Antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03424-12","article-title":"Multiple Pathways of Escape From HIV Broadly Cross-Neutralizing V2-Dependent Antibodies","volume":"87","author":"Moore","year":"2013","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jim.2011.09.007","article-title":"Development and Implementation of an International Proficiency Testing Program for a Neutralizing Antibody Assay for HIV-1 in TZM-Bl Cells","volume":"375","author":"Todd","year":"2012","journal-title":"J Immunol Methods"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and Validation of the TZM-Bl Assay for Standardized Assessments of Neutralizing Antibodies Against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.16.10103-10107.2005","article-title":"Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines","volume":"79","author":"Mascola","year":"2005","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep38177","article-title":"Structural Basis for Broad Neutralization of HIV-1 Through the Molecular Recognition of 10E8 Helical Epitope at the Membrane Interface","volume":"6","author":"Rujas","year":"2016","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1912427116","article-title":"Topological Analysis of the Gp41 MPER on Lipid Bilayers Relevant to the Metastable HIV-1 Envelope Prefusion State","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1807259115","article-title":"Structure of the Membrane Proximal External Region of HIV-1 Envelope Glycoprotein","volume":"115","author":"Fu","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1004271","DOI":"10.1371\/JOURNAL.PPAT.1004271","article-title":"Antibody to Gp41 MPER Alters Functional Properties of HIV-1 Env Without Complete Neutralization","volume":"10","author":"Kim","year":"2014","journal-title":"PloS Pathog"},{"key":"B51","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","article-title":"Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody Ln01","volume":"26","author":"Pinto","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.013","article-title":"Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation","volume":"19","author":"Zhou","year":"2017","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Doria-Rose","year":"2015","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01909-20","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies Against Primary African Isolates","volume":"95","author":"Lorenzi","year":"2021","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies Against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"Cohen","year":"2017","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-019-08658-4","article-title":"Improvement of Antibody Functionality by Structure-Guided Paratope Engraftment","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212649","article-title":"Introduction of the YTE Mutation Into the Non-Immunogenic HIV bnAb PGT121 Induces Anti-Drug Antibodies in Macaques","volume":"14","author":"Rosenberg","year":"2019","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.06.002","article-title":"AAV-Mediated Expression of Broadly Neutralizing and Vaccine-Like Antibodies Targeting the HIV-1 Envelope V2 Region","volume":"14","author":"van den Berg","year":"2019","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12478","article-title":"Antibody Gene Transfer With Adeno-Associated Viral Vectors as a Method for HIV Prevention","volume":"275","author":"Brady","year":"2017","journal-title":"Immunol Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/antib2020193","article-title":"In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments","volume":"2","author":"Monnier","year":"2013","journal-title":"Antibodies"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0200060","DOI":"10.1371\/journal.pone.0200060","article-title":"Development and Testing of AAV-Delivered Single-Chain Variable Fragments for the Treatment of Methamphetamine Abuse","volume":"13","author":"Hay","year":"2018","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0152589","DOI":"10.1371\/journal.pone.0152589","article-title":"Self-Complementary Adeno-Associated Virus Vectors Improve Transduction Efficiency of Corneal Endothelial Cells","volume":"11","author":"Gruenert","year":"2016","journal-title":"PloS One"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus","volume":"7","author":"Dong","year":"2008","journal-title":"Hum Gene Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.255","article-title":"Effect of Genome Size on AAV Vector Packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic Comparison of 2A Peptides for Cloning Multi-Genes in a Polycistronic Vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.48","article-title":"Self-Complementary Adeno-Associated Viral Vectors for Gene Therapy of Hemophilia B: Progress and Challenges","volume":"4","author":"Raj","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-Associated Virus-Mediated Delivery of a Recombinant Single-Chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104770","article-title":"Neuronally Expressed Anti-Tau scFv Prevents Tauopathy-Induced Phenotypes in Drosophila Models","volume":"137","author":"Krishnaswamy","year":"2020","journal-title":"Neurobiol Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3658","article-title":"Targeted DNA Demethylation In Vivo Using Dcas9-Peptide Repeat and scFv-TET1 Catalytic Domain Fusions","volume":"34","author":"Morita","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.057","article-title":"In Vitro and In Vivo Evaluation of a Single Chain Antibody Fragment Generated in Planta With Potent Rabies Neutralisation Activity","volume":"37","author":"Phoolcharoen","year":"2019","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acs.bioconjchem.7b00592","article-title":"Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting","volume":"29","author":"Greineder","year":"2018","journal-title":"Bioconjug Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted Delivery of a PD-1-Blocking scFV by CAR-T Cells Enhances Anti-Tumor Efficacy In Vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.734110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:08:37Z","timestamp":1631768917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.734110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2021.734110"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.734110","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"734110"}}